The prevalence of hyperlipidaemia and related clinical features in insulin-dependent diabetes mellitus - PubMed (original) (raw)
. 1989 Mar;70(263):265-76.
Affiliations
- PMID: 2602538
The prevalence of hyperlipidaemia and related clinical features in insulin-dependent diabetes mellitus
P H Winocour et al. Q J Med. 1989 Mar.
Abstract
The prevalence of hyperlipidaemia and related clinical features was examined in 205 individuals with insulin-dependent diabetes mellitus. Overall, 40 per cent (82) of the individuals had hyperlipidaemia. Whilst the prevalence of hypertriglyceridaemia and combined hyperlipidaemia was greater in patients with insulin-dependent diabetes mellitus than non-diabetics, this was not the case for hypercholesterolaemia. Hyperlipidaemia was present in older patients, and the daily insulin dose and levels of HbA1 were highest in those with combined hyperlipidaemia. In addition normolipidaemic subjects had the lowest levels of serum creatinine. Triglyceride levels were predicted (in order of importance) by insulin dose, age at diagnosis, HbA1 and body mass index, whilst cholesterol levels were predicted by the age at the time of study, body mass index, urinary protein excretion, and levels of fasting blood glucose and HbA1. Hyperlipidaemia is common in insulin-dependent diabetes mellitus, and may be particularly apparent in older patients and/or those with early renal dysfunction or poor glycaemic control.
Similar articles
- Some factors indicative of hypertriglyceridemia in patients investigated for diabetes mellitus.
Rodger NW, Du EL. Rodger NW, et al. Can Med Assoc J. 1973 Sep 1;109(5):363-8. Can Med Assoc J. 1973. PMID: 4742474 Free PMC article. - Prevalence of lipid abnormalities in Sri Lankan patients with non-insulin dependent diabetes mellitus.
Siribaddana S, Perera N, Perera S, Fernando D, Weerasuriya N. Siribaddana S, et al. Ceylon Med J. 1994 Mar;39(1):22-5. Ceylon Med J. 1994. PMID: 8194142 Clinical Trial. - Implications of decreased serum adiponectin for type IIb hyperlipidaemia and increased cholesterol levels of very-low-density lipoprotein in type II diabetic patients.
Yoshida H, Hirowatari Y, Kurosawa H, Tada N. Yoshida H, et al. Clin Sci (Lond). 2005 Sep;109(3):297-302. doi: 10.1042/CS20040353. Clin Sci (Lond). 2005. PMID: 15907189 - Dyslipidemias in patients with diabetes mellitus: classification and risks and benefits of therapy.
Oki JC. Oki JC. Pharmacotherapy. 1995 May-Jun;15(3):317-37. Pharmacotherapy. 1995. PMID: 7667166 Review. - [Diabetes mellitus and lipoproteins].
Somogyi A. Somogyi A. Orv Hetil. 1993 Oct 24;134(43):2371-7. Orv Hetil. 1993. PMID: 8233456 Review. Hungarian.
Cited by
- Delayed catabolism of apoB-48 lipoproteins due to decreased heparan sulfate proteoglycan production in diabetic mice.
Ebara T, Conde K, Kako Y, Liu Y, Xu Y, Ramakrishnan R, Goldberg IJ, Shachter NS. Ebara T, et al. J Clin Invest. 2000 Jun;105(12):1807-18. doi: 10.1172/JCI8283. J Clin Invest. 2000. PMID: 10862796 Free PMC article. - Measurement of apolipoproteins in the diabetic clinic.
Mazurkiewicz JC, Watts GF. Mazurkiewicz JC, et al. J R Soc Med. 1993 Feb;86(2):122. J R Soc Med. 1993. PMID: 8433305 Free PMC article. No abstract available. - Specific lipid lowering therapy in the management of diabetes.
Durrington PN. Durrington PN. Postgrad Med J. 1991 Oct;67(792):947-52. doi: 10.1136/pgmj.67.792.947. Postgrad Med J. 1991. PMID: 1758809 Free PMC article. Review. No abstract available. - Treatment of diabetes: the effect on serum lipids and lipoproteins.
Merrin PK, Elkeles RS. Merrin PK, et al. Postgrad Med J. 1991 Oct;67(792):931-7. doi: 10.1136/pgmj.67.792.931. Postgrad Med J. 1991. PMID: 1758807 Free PMC article. Review. No abstract available.
MeSH terms
Substances
LinkOut - more resources
Medical
Miscellaneous